The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | CAR-T for NHL: a first real-world study
Karl Kilgore, PhD, Avalere Health, An Inovalon Company, Bowie, MD, discusses the real-world data study describing the demographic and clinical characteristics of Medicare patients receiving CAR-T therapy (axicabtagene ciloleucel or tisagenlecleucel), and comparing healthcare utilization, costs, and outcomes pre and post-CAR T-cell therapy. The results of this study reveal that older patients with multiple comorbidities can be treated successfully with CAR T-cell therapy, and that post-index care was associated with lower hospitalization rates, bed days, emergency department visits, and lower total costs during this period. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
